Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 848 across all filing types
Latest filing 2018-08-17 Capital/Financing Update
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for offering securities, including common stock, preferred stock, warrants, debt securities, rights, and units, with an aggregate offering price up to $75 million. The document includes details about the registration, offering terms, and legal disclaimers. It is not a financial report, earnings release, or management discussion, but a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report, so it is not RPA or RNS. Confidence is high due to clear identification of the form and content.
2018-08-17 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-08-10 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2018, reporting the results of operations and financial condition for the quarter ended June 30, 2018. It mentions a press release and a conference call regarding quarterly results. The document does not contain the full financial statements or detailed financial analysis itself but references a press release and a conference call. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. The length of the document (6880 characters) and the content focusing on announcing results and a conference call further support this classification. Therefore, the filing type is Earnings Release (ER).
2018-08-09 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-01 English
FORM 3 SUBMISSION
Director's Dealing
2018-08-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.